Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822120 · ClinicalTrials.gov registry record · Phase 2
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 371
- Enrollment target
NCT00822120 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 371 participants.
The verdict
NCT00822120, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 371 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- BIOLOGICAL bleomycin sulfate
- DRUG ABVD regimen
- DRUG BEACOPP regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2009-07 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822120
The ClinicalTrials.gov registry entry for NCT00822120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00822120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00822120 about?
NCT00822120 is a clinical study titled "S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receivin...
What is the current status of trial NCT00822120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 371 participants. The study started on 2009-07. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT00822120?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), bleomycin sulfate (BIOLOGICAL), ABVD regimen (DRUG), BEACOPP regimen (DRUG).
Who is sponsoring clinical trial NCT00822120?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.